Second Sight Medical Products

Equities

EYES

US81362J3086

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
1.73 USD -3.89% Intraday chart for Second Sight Medical Products -5.98% -24.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vivani Medical Starts Nasdaq Trading Lower MT
Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index CI
Second Sight Medical Completes Merger With Nano Precision Medical; Changes Name to Vivani Medical MT
Nano Precision Medical, Inc. completed the acquisition of Second Sight Medical Products, Inc. in a reverse merger transaction. CI
Second Sight Medical Products Starts Trading on Split-Adjusted Basis; Shares Down MT
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Second Sight Medical Products, Inc. Announces Resignation of Edward Randolph as its Chief Operating Officer, Effective August 19, 2022 CI
Second Sight Medical Products, Inc. has Changed its Name to Vivani Medical, Inc CI
Second Sight Medical Products Receives $1.1 Million of Funding for Visual Cortical Prosthesis Trial MT
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study CI
Second Sight Medical Products, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
North American Morning Briefing : Dow Futures -2- DJ
North American Morning Briefing : Stock Futures -3- DJ
Transcript : Nano Precision Medical, Inc., Second Sight Medical Products, Inc. - M&A Call
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal MT
Nano Precision Medical, Inc. entered into term sheet to acquire Second Sight Medical Products, Inc. for approximately $180 million in a reverse merger transaction. CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Second Sight Medical Products, Inc.(NasdaqCM:EYES) added to S&P Global BMI Index CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Second Sight Medical Products : Obtains New NIH Grant Supplement for Visual Neuroprostheses Study MT
Second Sight Medical Products, Inc. Receives Grant from the National Institutes of Health CI
North American Morning Briefing : Stock Futures -3- DJ
Certain Common Stock of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021. CI
Certain Stock Options of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021. CI
Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021. CI
Chart Second Sight Medical Products
More charts
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. EYES Stock
  4. News Second Sight Medical Products
  5. Second Sight Medical Products : Obtains New NIH Grant Supplement for Visual Neuroprostheses Study